Announcement on Convening the 2025 Semi-annual Performance Briefing
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening the 2025 Semi-annual Performance Briefing
Filed with SSE · · 2 pages · Chinese
Release
Beijing Konruns Pharmaceutical Co., Ltd. on 6ix
Earlier from Beijing Konruns Pharmaceutical
- Announcement on Release of Pledge of Partial Shares of Controlling Shareholders
- Announcement on Results of Shareholding Reduction by Senior Management Members
- Announcement on Receipt of Clinical Trial Approval Notice for KC1036 in Combination with PD-1 Antibody and Platinum-based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Announcement on Lifting Sales Restrictions and Listing for Circulation in the 2nd Restriction Period for the 1st Grant under 2023 Restricted Stock Incentive Plan
- Pilot Project of the Center for Drug Evaluation
Later from Beijing Konruns Pharmaceutical
- Announcement on Resolutions of the 16th Meeting of the 4th Board of Supervisors
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- Announcement on Repurchasing Shares through Call Auction for the 1st Time and Progress in Share Repurchase
- Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders Not Subject to Sales Restrictions Concerning Share Repurchase
- Report for Q3 2025
Follow Beijing Konruns Pharmaceutical into a list and get an email when it puts out news.
Follow Beijing Konruns Pharmaceutical